All In Biotech

Drug Trial Radar · NCT04305054

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 335 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

335

Actual

Start

Jul 1, 2020

Primary completion

May 18, 2026

Study completion May 18, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study. Researchers want to know if adding other treatments to pembrolizumab can treat advanced melanoma. The goals of this study are to learn: * About the safety and how well people tolerate pembrolizumab given with other treatments * How many people have melanoma that responds (gets smaller or goes away) to treatment

Conditions

  • Melanoma

Interventions

  • PembrolizumabBiological

    Administered via IV infusion at a specified dose on specified days

  • VibostolimabBiological

    Administered via IV infusion at a specified dose on specified days

  • Pembrolizumab/QuavonlimabBiological

    Administered via IV infusion at a specified dose on specified days

  • LenvatinibDrug

    Administered via oral capsule at a specified dose on specified days

  • Favezelimab/PembrolizumabBiological

    Administered via IV infusion at a specified dose on specified days

  • ATRADrug

    Administered via oral capsule at a specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who experience a dose-limiting toxicity (DLT): Safety lead-in phaseTime frame: Up to ~3 weeks
  2. Percentage of participants who experience an adverse event (AE): Safety lead-inTime frame: Up to ~3 weeks
  3. Percentage of participants who discontinue study treatment due to an AE: Safety lead-inTime frame: Up to ~3 weeks
  4. Percentage of participants who experience an adverse event (AE)Time frame: Up to ~28 months
  5. Percentage of participants who discontinue study treatment due to an AETime frame: Up to ~24 months
  6. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)Time frame: Up to ~30 months

Locations

60 sites in 14 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute ( Site 2009)

    Los Angeles, California

  • UCLA Hematology & Oncology ( Site 2004)

    Los Angeles, California

  • Providence Saint John's Health Center ( Site 2010)

    Santa Monica, California

  • University of Colorado, Anschutz Cancer Pavilion ( Site 2012)

    Aurora, Colorado

  • University of Florida College of Medicine-UF Health Cancer Center/Clinical Trials Office ( Site 2026)

    Gainesville, Florida

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 2022)

    Baltimore, Maryland

  • R.J. Zuckerberg Cancer Center ( Site 2032)

    Lake Success, New York

  • NYU Clinical Cancer Center ( Site 2002)

    New York, New York

  • Duke Cancer Institute ( Site 2005)

    Durham, North Carolina

  • Martha Morehouse Tower ( Site 2020)

    Columbus, Ohio

  • Oregon Health & Science University ( Site 2013)

    Portland, Oregon

  • University of Pennsylvania Abramson Cancer Center ( Site 2008)

    Philadelphia, Pennsylvania

  • West Cancer Center - East Campus ( Site 2014)

    Germantown, Tennessee

  • Mays Cancer Center ( Site 2025)

    San Antonio, Texas

  • Inova Schar Cancer Institute ( Site 2011)

    Fairfax, Virginia

  • Sanatorio Finochietto ( Site 2245)

    Buenos Aires, Argentina

  • Clinica Adventista Belgrano-Oncology ( Site 2242)

    Caba., Buenos Aires, Argentina

  • Instituto Alexander Fleming-Alexander Fleming ( Site 2243)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Calvary Mater Newcastle-Medical Oncology ( Site 2404)

    Waratah, New South Wales, Australia

  • Melanoma Institute Australia ( Site 2402)

    Wollstonecraft, New South Wales, Australia

  • Tasman Oncology Research Pty Ltd ( Site 2403)

    Southport, Queensland, Australia

  • Fiona Stanley Hospital ( Site 2401)

    Murdoch, Western Australia, Australia

  • CIDO SpA-Oncology ( Site 2256)

    Temuco, Araucania, Chile

  • IC La Serena Research ( Site 2254)

    La Serena, Coquimbo Region, Chile

  • FALP-UIDO ( Site 2251)

    Santiago, Region M. de Santiago, Chile

  • Oncovida ( Site 2257)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill ( Site 2252)

    Santiago, Region M. de Santiago, Chile

  • Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 2261)

    Bogotá, Bogota D.C., Colombia

  • Fundación Valle del Lili ( Site 2265)

    Cali, Valle del Cauca Department, Colombia

  • A.P.H. Paris, Hopital Saint Louis ( Site 2107)

    Paris, France

  • Hopital La Timone ( Site 2103)

    Marseille, Bouches-du-Rhone, France

  • CHU de Bordeaux- Hopital Saint Andre ( Site 2108)

    Bordeaux, Gironde, France

  • Institut Claudius Regaud ( Site 2105)

    Toulouse, Haute-Garonne, France

  • Gustave Roussy ( Site 2101)

    Villejuif, Île-de-France Region, France

  • C.H. Lyon Sud ( Site 2102)

    Pierre-Bénite, Rhone, France

  • European Interbalkan Medical Center-Oncology Department ( Site 2211)

    Thessaloniki, Greece

  • General Hospital of Athens "Laiko"-First Department of Internal Medicine ( Site 2212)

    Athens, Attica, Greece

  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ ( Site 2221)

    Szeged, Csongrád megye, Hungary

  • HaEmek Medical Center ( Site 2703)

    Afula, Israel

  • Rambam Health Care Campus-Oncology ( Site 2704)

    Haifa, Israel

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.